Keywords: novartis, marks, five, glivec, milestone, strong, cml

Novartis marks five year Glivec milestone with strong CML data

Article | 15 May 2006

Print This

Swiss drug major Novartis says that recent data, marking four and a half years since Gleevec/Glivec (imatinib), its treatment ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in